## Maria Tsokos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11604274/publications.pdf

Version: 2024-02-01

71102 155660 4,776 61 41 55 citations h-index g-index papers 63 63 63 5265 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Carney triad, SDH-deficient tumors, and Sdhb+ $l\hat{a}^{\gamma}$ mice share abnormal mitochondria. Endocrine-Related Cancer, 2015, 22, 345-352.	3.1	23
2	Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. Frontiers in Oncology, 2014, 4, 324.	2.8	80
3	Lymphangitic Retroperitoneal Carcinomatosis Occurring From Metastatic Sarcomatoid Chromophobe Renal Cell Carcinoma. Urology Case Reports, 2014, 2, 39-42.	0.3	1
4	Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor. Cancer Discovery, 2013, 3, 648-657.	9.4	288
5	Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors. Journal of Clinical Oncology, 2012, 30, 4141-4147.	1.6	93
6	CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy, 2012, 8, 1628-1642.	9.1	89
7	Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Related Tumors. Pediatric and Developmental Pathology, 2012, 15, 108-126.	1.0	66
8	Endogenous Thrombospondin-1 Regulates Leukocyte Recruitment and Activation and Accelerates Death from Systemic Candidiasis. PLoS ONE, 2012, 7, e48775.	2.5	31
9	Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biology, 2011, 30, 154-161.	3.6	60
10	UOK 262 cell line, fumarate hydratase deficient (FHâ^'/FHâ^') hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics, 2010, 196, 45-55.	1.0	131
11	Interferon-Â-Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo. Clinical Cancer Research, 2009, 15, 6602-6608.	7.0	30
12	Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling. Science Translational Medicine, 2009, 1, 3ra7.	12.4	145
13	The UOK 257 cell line: a novel model for studies of the human Birt–Hogg–Dubé gene pathway. Cancer Genetics and Cytogenetics, 2008, 180, 100-109.	1.0	55
14	Treatment of liver ischemia–reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery, 2008, 144, 752-761.	1.9	72
15	Thrombospondin-1 and CD47 Limit Cell and Tissue Survival of Radiation Injury. American Journal of Pathology, 2008, 173, 1100-1112.	3.8	77
16	Thrombospondin 1 Promotes Tumor Macrophage Recruitment and Enhances Tumor Cell Cytotoxicity of Differentiated U937 Cells. Cancer Research, 2008, 68, 7090-7099.	0.9	109
17	A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. Clinical Cancer Research, 2008, 14, 4850-4858.	7.0	142
18	Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the <i>Succinate Dehydrogenase Subunit B</i> Gene. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4826-4832.	3.6	111

#	Article	IF	Citations
19	Blockade of Thrombospondin-1-CD47 Interactions Prevents Necrosis of Full Thickness Skin Grafts. Annals of Surgery, 2008, 247, 180-190.	4.2	82
20	Increasing Survival of Ischemic Tissue by Targeting CD47. Circulation Research, 2007, 100, 712-720.	4.5	121
21	Blocking Thrombospondin-1/CD47 Signaling Alleviates Deleterious Effects of Aging on Tissue Responses to Ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2582-2588.	2.4	88
22	Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide–mediated vascular smooth muscle relaxation. Blood, 2007, 109, 1945-1952.	1.4	109
23	Sensitive Ewing sarcoma and neuroblastoma cell lines have increased levels of BAD expression and decreased levels of BAR expression compared to resistant cell lines. Cancer Letters, 2007, 247, 110-114.	7.2	6
24	Interferon- $\hat{I}^3$ Sensitizes Resistant Ewing's Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity. American Journal of Pathology, 2007, 170, 1917-1930.	3.8	43
25	Effectiveness of chemotherapy in non-rhabdomyosarcoma soft tissue sarcomas-response. Pediatric Blood and Cancer, 2005, 45, 228-228.	1.5	0
26	Hereditary Leiomyomatosis Associated with Bilateral, Massive, Macronodular Adrenocortical Disease and Atypical Cushing Syndrome: A Clinical and Molecular Genetic Investigation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3773-3779.	3.6	90
27	Interferon γ Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis–Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing's Sarcoma. Cancer Research, 2004, 64, 8349-8356.	0.9	74
28	Cyclical Cushing Syndrome Presenting in Infancy: An Early Form of Primary Pigmented Nodular Adrenocortical Disease, or a New Entity?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3173-3182.	3.6	105
29	Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency. Human Molecular Genetics, 2003, 12, 1631-1641.	2.9	153
30	Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Research, 2003, 63, 1122-9.	0.9	88
31	Cholesterol storage defect in RSH/Smith–Lemli–Opitz syndrome fibroblasts. Molecular Genetics and Metabolism, 2002, 75, 325-334.	1.1	52
32	Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. Medical and Pediatric Oncology, 2002, 38, 158-164.	1.0	143
33	Molecular Confirmation of Ewing Sarcoma. The American Journal of Pediatric Hematology/oncology, 2001, 23, 221-224.	1.3	59
34	Ewing sarcoma and sinonasal neuroectodermal tumors as second malignant tumors after retinoblastoma and other neoplasms. Medical and Pediatric Oncology, 2001, 36, 290-294.	1.0	25
35	Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nature Genetics, 2001, 27, 209-214.	21.4	451
36	The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma. Oncogene, 2001, 20, 3217-3225.	5.9	42

#	Article	IF	Citations
37	Interdigitating Dendritic Cell Sarcoma. American Journal of Clinical Pathology, 2001, 115, 589-597.	0.7	129
38	Inguinal hernia in patients with Ewing sarcoma: A clue to etiology. , 2000, 34, 195-199.		19
39	Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene, 2000, 19, 6082-6090.	5.9	37
40	Caffeic Acid Phenethyl Ester Induces Leukocyte Apoptosis, Modulates Nuclear Factor-Kappa B and Suppresses Acute Inflammation. NeuroImmunoModulation, 2000, 7, 99-105.	1.8	147
41	Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2924-2932.	3.6	59
42	Hemihypertrophy and a poorly differentiated embryonal rhabdomyosarcoma of the pelvis., 1999, 32, 38-43.		19
43	Myc Oncogene Expression and Nude Mouse Tumorigenicity and Metastasis Formation Are Higher in Alveolar than Embryonal Rhabdomyosarcoma Cell Lines. Pediatric Research, 1999, 45, 552-558.	2.3	27
44	Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2924-2932.	3.6	17
45	Telomerase activity in precancerous hepatic nodules. Cancer, 1998, 82, 1831-1838.	4.1	78
46	Fas Ligand Is Present in Tumors of the Ewing's Sarcoma Family and Is Cleaved into a Soluble Form by a Metalloproteinase. American Journal of Pathology, 1998, 153, 1947-1956.	3.8	74
47	Fas/Fas Ligand Up-Regulation and BCL-2 Down-Regulation May Be Significant in the Pathogenesis of Hashimoto's Thyroiditis. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2199-2203.	3.6	64
48	Telomerase activity in precancerous hepatic nodules. Cancer, 1998, 82, 1831-1838.	4.1	3
49	Reticulum Cell Neoplasms of Lymph Nodes. American Journal of Surgical Pathology, 1998, 22, 1048-1058.	3.7	132
50	An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript. Human Pathology, 1997, 28, 502-509.	2.0	69
51	The aggregated form of an AAMP derived peptide behaves as a heparin sensitive cell binding agent. , 1997, 54, 365-372.		3
52	Radiographic findings in type 3 b Gaucher disease. Pediatric Radiology, 1996, 26, 852-860.	2.0	21
53	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors., 1996, 78, 901-911.		112
54	Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470., 1996, 68, 596-599.		18

#	Article	IF	CITATION
55	Interferon-Î <sup>3</sup> induced cell death in a cultured human salivary gland cell line. , 1996, 167, 297-304.		61
56	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer, 1996, 78, 901-911.	4.1	77
57	Cutaneous Lymphocytic Vasculopathy in Lymphoproliferative Disorders-A Paraneoplastic Lymphocytic Vasculitis of the Skin. Leukemia and Lymphoma, 1995, 16, 477-482.	1.3	33
58	Gastrointestinal Autonomic Nerve Tumor. Ultrastructural Pathology, 1991, 15, 49-55.	0.9	35
59	Primary Pigmented Nodular Adrenocortical Disease. American Journal of Surgical Pathology, 1989, 13, 921-930.	3.7	46
60	Vasculitis in Primary Sjögren's Syndrome: Histologic Classification and Clinical Presentation. American Journal of Clinical Pathology, 1987, 88, 26-31.	0.7	91
61	Idiopathic Midline Destructive Disease (IMDD): A Subgroup of Patients with the "Midline Granuloma― Syndrome. American Journal of Clinical Pathology, 1982, 77, 162-168.	0.7	70